Efficacy of Suvorexant in Patients With Effectively Treated Restless Legs Syndrome and Persistent Chronic Insomnia

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

46 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-08-12

Study Completion Date

2023-10-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators aim to determine the effect of suvorexant on actigraphically-derived total sleep time in patients with effectively treated restless legs syndrome with persistent insomnia in a two-arm, double-blind, randomized placebo-controlled crossover 2.5-month trial.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes

NCT03818581

Type 2 Diabetes Mellitus Insomnia Sleep Disorder +1 more

COMPLETED PHASE4

Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study B (MK-4305-029)

NCT01097629

Primary Insomnia

COMPLETED PHASE3

A Long Term Safety Study of Suvorexant in Participants With Primary Insomnia (MK-4305-009 AM3)

NCT01021813

Insomnia

COMPLETED PHASE3

Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Participants With Alzheimer's Disease (MK-4305-061)

NCT02750306

Sleep Initiation and Maintenance Disorders Alzheimer Disease

COMPLETED PHASE3

Phase IIB 2-Period Crossover Polysomnography Study in Participants With Primary Insomnia (MK-4305-006)

NCT00792298

Primary Insomnia

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Restless Legs Syndrome (RLS) is a sensory-motor neurological disorder characterized by an irresistible urge to move the legs. Persistent difficulties with all phases of sleep are common in patients whose RLS symptoms are resolved with treatment. Multiple potential causes for treatment-refractory sleep disturbance exist, including activating effects of dopamine agonists (which are first-line RLS treatments), conditioned insomnia and poor sleep habits as a result of chronic RLS-related sleep disturbance, and comorbid medical and psychiatric illness. Suvorexant provides an important therapeutic option to treat insomnia in the context of RLS. It has demonstrated long-term efficacy, particularly in shortening the duration of nocturnal awakenings and increasing total sleep time. Similarly, it has a comparatively benign side effect profile compared to many other agents typically prescribed to treat insomnia. The investigators aim to determine the effect of suvorexant on actigraphically-derived total sleep time, as well as actigraphically-derived wake after sleep onset, Insomnia Severity Index score, subjective sleep endpoints, and RLS symptom severity.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Restless Legs Syndrome Insomnia Sleep Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Subjects will be randomized in a 1:1 ratio to suvorexant 10-20 mg or equivalent placebo for four weeks followed by crossover (after a 2-week washout) to the alternate treatment.

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

The participant, investigator, and clinical research coordinator will remain masked throughout the duration of the study.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment --> Placebo

This group will receive suvorexant during the first 4-week phase, and placebo during the second 4-week phase.

Group Type EXPERIMENTAL

Suvorexant

Intervention Type DRUG

10-mg or 20-mg suvorexant capsules

Placebo

Intervention Type OTHER

Matching placebo capsules

Placebo --> Treatment

This group will receive placebo during the first 4-week phase, and suvorexant during the second 4-week phase.

Group Type EXPERIMENTAL

Suvorexant

Intervention Type DRUG

10-mg or 20-mg suvorexant capsules

Placebo

Intervention Type OTHER

Matching placebo capsules

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Suvorexant

10-mg or 20-mg suvorexant capsules

Intervention Type DRUG

Placebo

Matching placebo capsules

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Belsomra

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Men or women of any ethnic origin
2. Written informed consent is obtained
3. Speaks and writes in English
4. A willingness and ability to comply with study procedures
5. Age 25-85 years
6. Diagnosis of RLS via Cambridge-Hopkins RLS questionnaire
7. International Restless Legs Syndrome Study Group scale score (IRLS) \< 15
8. RLS treatment with a dopaminergic agonist or an alpha-2-delta agent
9. No changes in RLS medication in the previous month
10. DSM-5 criteria for Insomnia Disorder
11. Report a total sleep time ≤ 7 hours and wake after sleep onset (WASO) \> 45 minutes on 7 or more of the 14 nightly sleep logs during both the initial 2-week screening period and the two-week screening run-in period. WASO does not decrease by more than 50% on the 2-week sleep diary obtained between the screening visit and the randomization visit

Exclusion Criteria

1. Diagnosis of moderate/severe obstructive sleep apnea (AHI \> 30) not using continuous positive airway pressure therapy (CPAP) (can be included if CPAP adherent), or other untreated primary sleep disorders (e.g. narcolepsy)
2. Shift workers
3. Unwillingness to not use sedative-hypnotics (other than suvorexant) during the study period
4. Unwillingness to maintain stable RLS medication during the study unless medically indicated
5. Current use of an opiate medication
6. Unwillingness to not take stimulants (e.g. caffeine) after 4:00 pm during the study
7. Current major depressive episode, by report and as indicated by the Patient Health Questionnaire (PHQ-9)
8. Lifetime history of bipolar disorder, psychosis, or other serious psychiatric illness
9. Current alcohol/substance use disorder
10. BMI ≥ 40 kg/m\^2
11. Renal or hepatic disease judged to interfere with drug metabolism and excretion
12. Pregnancy or breastfeeding
13. Malignancy within past 2 years
14. Surgery within past 3 months
15. Neurological disorder or cardiovascular disease raising safety concerns about use of suvorexant and/or judged to interfere with ability to assess efficacy of the treatment
16. Medical instability considered to interfere with study procedures
17. Concomitant medications with drug interaction or co-administration concerns
18. Contraindications or allergic responses to suvorexant
19. History of being treated with suvorexant
20. Travel across two time-zones during the week prior to enrollment
21. Greater than 6 cups of coffee per day

Minimum Eligible Age

25 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No